Company: PTPI
Filing Date: 2025-03-14
Form Type: PRER14A
Source: 0001104659-25-024012
Chunk: 82

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-14
Form: PRER14A
Chunk 82
---

the Company or any of its subsidiaries.

(e)
“” shall mean the Chief Executive Officer of the Company.

<div align='center'>C-1</div>

(f)
A “” shall be deemed to have occurred if:

(i) the
acquisition, directly or indirectly, by a “person” (within the meaning of Section 13(d)(3) of the Exchange Act)
(a “”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of
more than 50% of the combined voting power of the voting securities of the Company entitled to vote generally in the election of directors
(the “”); provided, however, that the following acquisitions of Voting Securities shall not constitute
a Change in Control: (A) any acquisition by or from the Company or any of its subsidiaries, or by any employee benefit plan (or
related trust) sponsored or maintained by the Company or any of its subsidiaries, (B) any acquisition by any underwriter in any
firm commitment underwriting of securities to be issued by the Company, or (C) any acquisition by any corporation (or other entity)
if, immediately following such acquisition, 50% or more of the then outstanding shares of common stock (or other equity unit) of such
corporation (or other entity) and the combined voting power of the then outstanding voting securities of such corporation (or other entity),
are beneficially owned, directly or indirectly, by all or substantially all of the individuals or entities who, immediately prior to
such acquisition, were the beneficial owners of the then outstanding shares of Common Stock and the Voting Securities in substantially
the same proportions, respectively, as their ownership immediately prior to the acquisition of the shares of Common Stock and Voting
Securities; or

(ii) the
consummation of the sale or other disposition of all or substantially all of the assets of the Company, other than to a wholly-owned
subsidiary of the Company or to a holding company of which the Company is a direct or indirect wholly owned subsidiary prior to such
transaction; or

(iii) the
consummation of a reorganization, merger or consolidation of the Company, other than a reorganization, merger or consolidation, which
would result in the Voting Securities outstanding immediately prior to the transaction continuing to represent (whether by remaining
outstanding or by being converted to voting securities of the surviving entity) 65% or more of the Voting Securities or the voting power
of